Neurogene (NGNE)
NASDAQ:NGNE
Top Page
Neurogene
(NASDAQ:NGNE)
Select Model
Select Model
Rating:53Neutral
Price Target:
$21.00
▲(3.19% Upside)
Action:ReiteratedDate:03/25/26
The score is held back primarily by weak financial performance driven by widening losses and increasing cash burn, despite low leverage. Offsetting this, corporate events are a meaningful positive with FDA Breakthrough Therapy designation and progressing registrational-trial milestones, while technicals are neutral and valuation metrics provide little support.
Positive Factors
Regulatory Progress (Breakthrough Therapy)
Breakthrough Therapy designation is a durable de-risking event: it can expedite review and enable more intensive FDA interactions, shortening development timelines and improving regulatory clarity. Over months this materially raises the probability of a viable approval path and strengthens partner interest.
Negative Factors
High Cash Burn
Sustained, large negative operating and free cash flow indicates rising cash consumption tied to clinical activities. Over the next 2-6 months this elevates funding risk: management may need to raise capital, which can dilute shareholders or require partnership agreements that cede economic upside.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory Progress (Breakthrough Therapy)
Breakthrough Therapy designation is a durable de-risking event: it can expedite review and enable more intensive FDA interactions, shortening development timelines and improving regulatory clarity. Over months this materially raises the probability of a viable approval path and strengthens partner interest.
Read all positive factors
Neurogene (NGNE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$316.94M
Dividend YieldN/A
Average Volume (3M)225.72K
Price to Earnings (P/E)―
Beta (1Y)2.95
Revenue Growth-100.00%
EPS Growth1.47%
CountryUS
Employees107
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.12
Shares Outstanding15,574,293
10 Day Avg. Volume272,921
30 Day Avg. Volume225,725
Financial Highlights & Ratios
PEG Ratio5.16
Price to Book (P/B)1.65
Price to Sales (P/S)0.00
P/FCF Ratio-5.57
Enterprise Value/Market Cap0.65
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-262.55
Enterprise Value/Ebitda-2.29
Forecast
1Y Price Target
$91.50Price Target Upside349.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-5.4
Revenue Forecast (FY)N/A
Neurogene Business Overview & Revenue Model
Company Description
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101...
How the Company Makes Money
null...
Neurogene Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
70
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 925.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -3.19M | -2.32M | -3.26M | -3.20M | -42.26M |
| EBITDA | -103.33M | -71.89M | -52.29M | -51.99M | -49.59M |
| Net Income | -90.35M | -75.14M | -36.32M | -55.19M | -50.52M |
Balance Sheet | |||||
| Total Assets | 288.60M | 335.73M | 222.57M | 109.27M | 101.49M |
| Cash, Cash Equivalents and Short-Term Investments | 269.01M | 312.40M | 197.16M | 82.02M | 70.54M |
| Total Debt | 9.89M | 12.43M | 16.25M | 4.69M | 6.43M |
| Total Liabilities | 23.72M | 25.36M | 36.55M | 10.64M | 193.36M |
| Stockholders Equity | 264.89M | 310.38M | 186.02M | 98.63M | -91.88M |
Cash Flow | |||||
| Free Cash Flow | -78.36M | -71.41M | -51.74M | -55.05M | -64.77M |
| Operating Cash Flow | -77.17M | -70.60M | -51.42M | -52.82M | -46.40M |
| Investing Cash Flow | 14.00M | -125.26M | 25.64M | -2.23M | -18.37M |
| Financing Cash Flow | 30.43M | 184.07M | 92.48M | 66.53M | 51.06M |
Neurogene Technical Analysis
Negative
20.35
Price Trends
19.53
Positive
20.61
Negative
21.27
Negative
Market Momentum
0.20
Positive
48.95
Neutral
59.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NGNE, the sentiment is Negative. The current price of 20.35 is below the 20-day moving average (MA) of 21.44, above the 50-day MA of 19.53, and below the 200-day MA of 21.27, indicating a neutral trend. The MACD of 0.20 indicates Positive momentum. The RSI at 48.95 is Neutral, neither overbought nor oversold. The STOCH value of 59.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NGNE.
Neurogene Risk Analysis
Neurogene disclosed 86 risk factors in its most recent earnings report. Neurogene reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Neurogene Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $407.92M | -1.84 | -46.34% | ― | ― | 14.33% | |
53 Neutral | $316.94M | -4.83 | -42.25% | ― | -100.00% | 1.47% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $192.06M | -3.95 | -977.67% | ― | ― | 17.36% | |
50 Neutral | $601.21M | -0.10 | 274.58% | ― | ― | -1072.48% | |
50 Neutral | $144.33M | -1.20 | -85.20% | ― | ― | 46.68% | |
44 Neutral | $232.86M | -6.10 | ― | ― | ― | ― |
* Healthcare Sector Average
NGNE
Neurogene
20.35
8.64
73.78%
SLN
Silence Therapeutics
4.93
2.11
74.82%
AVIR
Atea Pharmaceuticals
5.12
2.13
71.24%
ELTX
Elicio Therapeutics
10.44
4.28
69.48%
VOR
Vor Biopharma
14.48
0.13
0.91%
TNYA
Tenaya Therapeutics
0.67
0.10
16.67%
Neurogene Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Neurogene Gains FDA Breakthrough Status for Rett Gene Therapy
Positive
Feb 26, 2026
On February 26, 2026, Neurogene announced that the U.S. Food and Drug Administration granted Breakthrough Therapy designation to NGN-401, its late-stage investigational AAV9 gene therapy for Rett syndrome. The decision was based on interim Phase 1...
Business Operations and StrategyProduct-Related Announcements
Neurogene outlines 2026 milestones for NGN-401 Rett therapy
Positive
Jan 12, 2026
On January 12, 2026, Neurogene reported recent progress and 2026 milestones for NGN-401, its investigational AAV9 gene therapy targeting Rett syndrome, highlighting that multiple participants were dosed in the Embolden registrational trial during ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.